Prokaryotics Inc., USA
Prokaryotics Inc., USA (a spin-out from from Merck & Co., Inc.) aim to develop a new antibiotic that targets the fundamentally essential biochemical assembly components of the Gram-negative outer membrane, an intrinsic barrier that naturally restricts antibiotic entry and ultimate efficacy. The most promising enzymes target for drug development in this regard is LspA.
Selmod SA, Switzerland have developed a novel class of gyrase inhibitors addressing the known target but overcoming fluoroquinolones resistance. With a lead candidate and three further candidates with a broad spectrum of activity against Gram-negative bacteria, Selmod’s project promises to be an innovative approach as a resistance breaking antibiotic.
University of Essen
The University of Essen, Germany have discovered in preclinical studies that specific forms of interferons are more efficient than the standard treatment. Based on that they engineered chimeric interferons with increased antiviral activity. These interferons could improve efficacy of future HBV therapy as well as protection from various viruses, including future pandemics.